Medical Weight Management
GLP-1 Programs
Physician-supervised Semaglutide, Tirzepatide, Liraglutide, and Retatrutide protocols — with on-site blood testing and insurance accepted. Because effective weight management requires more than just a prescription.
Why Choose Sanavital
More Than Just a Prescription
Unlike clinics that only hand you an injection, our GLP-1 programs are built around your complete health picture — labs, monitoring, and clinical nutrition all included.
We Accept All Health Insurance
As a primary care center, we work with all major insurance providers for evaluations and blood work.
On-Site Blood Testing
Complete labs done in-house — baseline before, monitoring during, and assessment after every protocol.
Physician-Supervised Protocols
Every patient is monitored by our clinical team with regular follow-ups and dosing adjustments.
Available Medications
Our GLP-1 Protocols
All protocols are prescribed after evaluation and blood work. Your clinical team selects the right medication based on your health profile, goals, and prior treatment history.
GLP-1 Receptor Agonist
Semaglutide
0.25mg–2.4mg weekly injection
Semaglutide is the gold-standard GLP-1 receptor agonist for medical weight management. Originally developed for type 2 diabetes, it has proven highly effective for chronic weight management by reducing appetite, slowing gastric emptying, and improving metabolic markers. At Sanavital, every Semaglutide protocol includes physician supervision, baseline and follow-up blood testing, and nutritional support.
Key Benefits
- Significant appetite suppression
- Clinically proven 15–17% body weight reduction
- Improves insulin sensitivity and blood sugar
- Reduces cardiovascular risk markers
- Weekly once-a-week dosing for convenience
Ideal For
- BMI ≥27 with weight-related health conditions
- Type 2 diabetes or pre-diabetes management
- Patients who have struggled with conventional diets
- Cardiovascular risk reduction alongside weight loss
GLP-1 + GIP Dual Agonist
Tirzepatide
2.5mg–15mg weekly injection
Tirzepatide is a breakthrough dual GLP-1 and GIP receptor agonist that delivers superior weight loss results compared to GLP-1 monotherapy alone. By activating two complementary metabolic pathways simultaneously, Tirzepatide achieves up to 22% body weight reduction in clinical trials. Our protocol includes comprehensive labs, structured dosing titration, and integrated nutritional guidance.
Key Benefits
- Dual-agonist action for superior weight loss
- Up to 22% body weight reduction in trials
- Better glycemic control than GLP-1 alone
- Improves cholesterol and triglyceride levels
- Once-weekly convenient dosing
Ideal For
- Patients seeking maximum weight loss results
- Type 2 diabetes with metabolic syndrome
- Plateaued on Semaglutide protocols
- Comprehensive cardiometabolic risk reduction
GLP-1 Receptor Agonist
Liraglutide
0.6mg–3mg daily injection
Liraglutide is a daily-dose GLP-1 receptor agonist that provides consistent appetite regulation and blood sugar management. As the first GLP-1 approved for weight management (Saxenda), it has an established safety profile and is suitable for patients who prefer daily dosing or cannot tolerate weekly injectables.
Key Benefits
- Daily dosing for consistent blood levels
- Well-established safety and efficacy profile
- Reduces appetite and caloric intake
- Cardiovascular outcome benefits proven
- Suitable for patients transitioning from Saxenda
Ideal For
- Patients preferring daily dosing schedule
- Those transitioning from brand Saxenda
- Cardiovascular risk reduction focus
- Type 2 diabetes management
GLP-1 + GIP + Glucagon Triple Agonist
Retatrutide
Individualized dosing protocol
Retatrutide is the most advanced GLP-1-class medication available, acting as a triple agonist on GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials have demonstrated up to 24% body weight reduction — the highest of any GLP-1 class agent. Available at Sanavital as part of our advanced protocol for patients seeking next-generation metabolic therapy.
Key Benefits
- Triple receptor agonism for maximum effect
- Up to 24% body weight reduction in trials
- Superior improvement in metabolic biomarkers
- Addresses obesity-related inflammation
- Next-generation metabolic therapy
Ideal For
- Patients who plateaued on dual agonists
- Severe obesity with multiple comorbidities
- Advanced metabolic syndrome management
- Seeking the most powerful available protocol
GLP-1 Receptor Agonist (Oral)
Oral Semaglutide
3mg–50mg daily oral tablet
Oral Semaglutide (Rybelsus equivalent) delivers the same active ingredient as injectable Semaglutide in a once-daily tablet. For patients with needle aversion or who prefer oral administration, this formulation provides the proven benefits of GLP-1 therapy in a convenient pill format.
Key Benefits
- No needles — 100% oral administration
- Same active ingredient as injectable Semaglutide
- Once-daily convenient dosing
- Proven weight loss and glycemic benefits
- Ideal for needle-averse patients
Ideal For
- Patients with needle aversion or phobia
- Those preferring oral over injectable therapy
- Type 2 diabetes with oral medication preference
- Maintenance after injectable GLP-1 program
Pricing varies based on medication dose, duration, and individual protocol design. Insurance may cover evaluation and lab work. Contact us for a personalized quote.
Your Journey
How Our GLP-1 Program Works
Initial Evaluation
Comprehensive health assessment and medical history review with our APRN.
On-Site Blood Work
Full metabolic panel, hormone levels, and key biomarkers drawn right here at the clinic.
Personalized Protocol
Your GLP-1 medication, starting dose, and titration schedule are designed around your results.
Ongoing Monitoring
Regular check-ins, dose adjustments, and repeat labs to track progress and optimize outcomes.
Ready to Start Your GLP-1 Protocol?
Schedule your initial evaluation. We accept all health insurance and perform on-site blood work at your first visit.